← All medicines

Cancer medicines

Vimseltinib

Independent educational summary · Sources checked November 20, 2026

A CSF1R-targeted kinase inhibitor for eligible symptomatic tenosynovial giant-cell tumors.

Profile scope: Vimseltinib. Confirm the exact product and route; formulations and combination products are not interchangeable.

Possible side effects

Fatigue, tingling, swelling around the eyes, or limb swelling may occur.

Serious risks and warning signs

Liver-test abnormalities and serious allergy require monitoring and assessment. Jaundice, dark urine, persistent nausea, or airway symptoms needs prompt contact. Its safety requirements should not be copied from a different drug for the same tumor.

A question for your healthcare team

What liver and other laboratory schedule applies, and which symptoms should trigger an immediate call?

What to do with this information

Discuss persistent or troubling symptoms with your prescriber or pharmacist. For severe breathing difficulty, collapse, a seizure, or inability to wake someone, seek emergency help. Read the linked medicine information for drug-specific instructions, including situations requiring immediate action. For routine treatment changes, consult your prescriber rather than changing your dose on your own. Follow the urgent action instructions above and in the linked medicine information.

Sources

Sources checked November 20, 2026. An original AI-assisted educational summary, not a complete adverse-effect or interaction list. This profile is part of the broader library expansion, not the original prescription-use ranking. Inclusion does not confirm current product availability or mean that risks outweigh benefits. This page has not been independently reviewed by a clinician.